ZA200703989B - Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1 - Google Patents
Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1Info
- Publication number
- ZA200703989B ZA200703989B ZA200703989A ZA200703989A ZA200703989B ZA 200703989 B ZA200703989 B ZA 200703989B ZA 200703989 A ZA200703989 A ZA 200703989A ZA 200703989 A ZA200703989 A ZA 200703989A ZA 200703989 B ZA200703989 B ZA 200703989B
- Authority
- ZA
- South Africa
- Prior art keywords
- ugt1a1
- atazanavir
- pharmacokinetics
- improving
- drugs metabolized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63294504P | 2004-12-03 | 2004-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200703989B true ZA200703989B (en) | 2008-09-25 |
Family
ID=36565812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200703989A ZA200703989B (en) | 2004-12-03 | 2007-05-17 | Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070259894A1 (https=) |
| EP (1) | EP1824957A4 (https=) |
| JP (1) | JP2008521934A (https=) |
| KR (1) | KR20070085702A (https=) |
| CN (1) | CN101068916A (https=) |
| AU (1) | AU2005311672B2 (https=) |
| BR (1) | BRPI0518741A2 (https=) |
| CA (1) | CA2588466A1 (https=) |
| IL (1) | IL183383A0 (https=) |
| MX (1) | MX2007006637A (https=) |
| NO (1) | NO20073403L (https=) |
| NZ (1) | NZ555215A (https=) |
| RU (1) | RU2403066C2 (https=) |
| WO (1) | WO2006060731A2 (https=) |
| ZA (1) | ZA200703989B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7491819B1 (en) | 2004-05-28 | 2009-02-17 | Bristol-Myers Squibb Company | N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| EP1819323B2 (en) | 2004-12-03 | 2023-03-22 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
| EP1904067B2 (en) | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| UA87884C2 (uk) | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| EP2116532B1 (en) | 2007-06-12 | 2011-12-07 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives as HIV protease inhibitors |
| US20100273203A1 (en) * | 2009-04-23 | 2010-10-28 | Board Of Trustees Of The University Of Arkansas | Methods and compositions for detecting metabolites |
| US8410064B2 (en) * | 2009-08-24 | 2013-04-02 | The Board Of Trustees Of The University Of Arkansas | Classical cannabinoid metabolites and methods of use thereof |
| WO2011026112A1 (en) * | 2009-08-31 | 2011-03-03 | The Board Of Trustees Of The University Of Arkansas | Compositions comprising specific ugt inhibitors and methods of use thereof |
| US9649311B2 (en) | 2009-10-26 | 2017-05-16 | Merck Sharp & Dohme Corp. | Solid pharmaceutical compositions containing an integrase inhibitor |
| US8883218B2 (en) * | 2010-03-26 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Anti-cancer nanoparticle compositions and methods of use |
| US9095598B2 (en) | 2010-12-28 | 2015-08-04 | The Board Of Trustees Of The University Of Arkansas | Stilbenoid derivatives and their uses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| PL360944A1 (en) * | 2000-10-12 | 2004-09-20 | Merck & Co, Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| ATE355064T1 (de) * | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| IL161337A0 (en) * | 2001-10-26 | 2004-09-27 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| US20030215462A1 (en) * | 2001-12-21 | 2003-11-20 | Wacher Vincent J. | Use of UGT inhibitors to increase bioavailability |
| NZ540729A (en) * | 2002-12-27 | 2008-03-28 | Angeletti P Ist Richerche Bio | Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors |
| US20040192624A1 (en) * | 2003-03-24 | 2004-09-30 | Kempf Dale J. | Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| EP1904067B2 (en) * | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| EP1819323B2 (en) * | 2004-12-03 | 2023-03-22 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
-
2005
- 2005-12-02 BR BRPI0518741-9A patent/BRPI0518741A2/pt not_active IP Right Cessation
- 2005-12-02 KR KR1020077012547A patent/KR20070085702A/ko not_active Withdrawn
- 2005-12-02 JP JP2007544571A patent/JP2008521934A/ja not_active Withdrawn
- 2005-12-02 CN CNA2005800413696A patent/CN101068916A/zh active Pending
- 2005-12-02 AU AU2005311672A patent/AU2005311672B2/en not_active Ceased
- 2005-12-02 US US11/792,189 patent/US20070259894A1/en not_active Abandoned
- 2005-12-02 WO PCT/US2005/043782 patent/WO2006060731A2/en not_active Ceased
- 2005-12-02 NZ NZ555215A patent/NZ555215A/en not_active IP Right Cessation
- 2005-12-02 EP EP05852867A patent/EP1824957A4/en not_active Withdrawn
- 2005-12-02 CA CA002588466A patent/CA2588466A1/en not_active Abandoned
- 2005-12-02 RU RU2007125130/15A patent/RU2403066C2/ru not_active IP Right Cessation
- 2005-12-02 MX MX2007006637A patent/MX2007006637A/es unknown
-
2007
- 2007-05-17 ZA ZA200703989A patent/ZA200703989B/xx unknown
- 2007-05-24 IL IL183383A patent/IL183383A0/en unknown
- 2007-07-02 NO NO20073403A patent/NO20073403L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008521934A (ja) | 2008-06-26 |
| RU2007125130A (ru) | 2009-01-10 |
| CA2588466A1 (en) | 2006-06-08 |
| KR20070085702A (ko) | 2007-08-27 |
| BRPI0518741A2 (pt) | 2008-12-02 |
| MX2007006637A (es) | 2007-06-19 |
| EP1824957A2 (en) | 2007-08-29 |
| US20070259894A1 (en) | 2007-11-08 |
| CN101068916A (zh) | 2007-11-07 |
| AU2005311672A1 (en) | 2006-06-08 |
| IL183383A0 (en) | 2007-09-20 |
| WO2006060731A3 (en) | 2006-09-28 |
| NZ555215A (en) | 2010-08-27 |
| RU2403066C2 (ru) | 2010-11-10 |
| NO20073403L (no) | 2007-08-31 |
| EP1824957A4 (en) | 2011-02-09 |
| AU2005311672B2 (en) | 2010-07-22 |
| WO2006060731A2 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200703989B (en) | Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1 | |
| HUS1600047I1 (hu) | Eljárások hipoglikémiás szerek beadására | |
| ZA200702382B (en) | Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines | |
| TWI369987B (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
| EG24362A (en) | Process for the preparation of dehydrogenated hydrocarbon compounds | |
| AP2037A (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| IL180916A0 (en) | Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | |
| IL192208A0 (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors | |
| IL181304A (en) | Use of dihydroprididone for the preparation of a drug for the treatment of spinal cord dysplasia | |
| IL160095A0 (en) | Formulations for poorly soluble drugs | |
| SI1710241T1 (sl) | Intermediatne spojine za pripravo trans-5-kloro-2-metil-2,3,3a, 12b-tetrahidro-1H-dibenz(2,3:6,7)oksepino(4,5-C)pirola | |
| TWI366457B (en) | Use of a beta2-adrenoceptor agonist for the preparation of a dermatological medicament | |
| IL182834A0 (en) | Sulfonamido-macrocycles and the salts thereof, a pharmaceutical composition comprisng these compounds, the method of preparing and the use thereof | |
| IL190323A0 (en) | Kit for the parenteral administration of drugs | |
| PT1615668E (pt) | Um medicamento para a terapia perioperatória em dois passos de tumores sólidos | |
| AU2002335304A1 (en) | The use of berberine as insulin sensitizer | |
| ZA200700755B (en) | Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | |
| ZA200806222B (en) | Methods for improving the pharmacokinetics of HIV integrase inhibitors | |
| IL177353A0 (en) | Process for the preparation of aq4n | |
| IL165414A0 (en) | Novel formulation for the parenteral application of crobenetine | |
| HK1120787A (en) | Mglur1 antagonists as therapeutic agents | |
| PL1600446T3 (pl) | Nowe pochodne 3,3-dimetylo-5-cyjano-benzoksepin użyteczne do otrzymywania pochodnych 5-formylo-benzoksepin | |
| HK1123735A (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors | |
| HK1094792A (en) | Process for the preparation of aq4n | |
| HU0400812D0 (en) | New pharmaceutical agents |